InhaleRx Limited (NX1) AI Stock Analysis

• Market Cap: AU$4.30M
• Dividend Yield: N/A
• Average Volume (3M): 66.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: N/A
• EPS Growth: -55.00%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 253,037,320
• 10 Day Avg. Volume: 164,400
• 30 Day Avg. Volume: 66,745
• PEG Ratio: 0.28
• Price to Book (P/B): -116.78
• Price to Sales (P/S): 22.29
• P/FCF Ratio: -20.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: AU$0.02 ▲(5.00% Upside)
• Action: Reiterated Date: 01/30/26
• Date: Action: Reiterated 01/30/26

The score is primarily held down by weak financial performance (volatile revenue, persistent large losses, negative operating/free cash flow, and negative equity). Technicals add additional pressure with a negative MACD and price below longer-term moving averages, while valuation is difficult to justify given the negative P/E and no dividend support.

Positive Factors

Low leverage

Absolute debt levels are very small (~34k) which limits interest burden and reduces refinancing pressure. Low financial leverage gives the company structural flexibility to prioritize operational stabilization or raise equity without immediate debt servicing constraints, helping medium-term resilience.

Negative Factors

Volatile, shrinking revenue

A 62% YoY revenue decline and prior volatility indicate an unstable commercial base and weak demand predictability. Structural revenue instability undermines scaling, makes long-term planning difficult, and increases reliance on one-off sales or funding to cover fixed costs and product development.

InhaleRx Limited Business Overview & Revenue Model

Company Description

InhaleRx Limited engages in the developing and commercializing of medical drug delivery systems in Australia. It also develops inhaled drug formulations. Its solutions include Medihale inhaler, a sealed pod inhaler for use with inhaled formulation...

Read more

InhaleRx Limited engages in the developing and commercializing of medical drug delivery systems in Australia. It also develops inhaled drug formulations. Its solutions include Medihale inhaler, a sealed pod inhaler for use with inhaled formulation...

How the Company Makes Money

InhaleRx Limited generates revenue primarily through the sale of its inhalation products, which are distributed to healthcare providers and pharmacies. The company may also engage in strategic partnerships with pharmaceutical firms to co-develop o...

Read more

InhaleRx Limited generates revenue primarily through the sale of its inhalation products, which are distributed to healthcare providers and pharmacies. The company may also engage in strategic partnerships with pharmaceutical firms to co-develop o...

InhaleRx Limited Financial Statement Overview

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

InhaleRx Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NX1, the sentiment is Negative. The current price of 0.02 is equal to the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.31 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NX1.

InhaleRx Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HMD	54 Neutral	AU$56.59M	-9.32	-417.72%	―	-34.06%	75.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CBL	48 Neutral	AU$24.72M	-1.40	-98.14%	―	14.84%	39.64%
UCM	43 Neutral	AU$3.12M	-0.88	-358.43%	―	-30.80%	-38.95%
NX1	42 Neutral	AU$4.30M	-2.37	296.01%	―	―	-55.00%
ADR	41 Neutral	AU$13.43M	-0.50	459.94%	―	-2.82%	32.47%
AT1	40 Underperform	AU$26.13M	-4.09	-58.40%	―	-7.20%	28.70%

InhaleRx Limited Corporate Events